Good afternoon, everyone, and thank you for joining BridgeBio Pharma's First Quarter 2026 Earnings Call. I'm Chinmay Shukla, Senior Vice President, Strategic Finance. With me are Neil Kumar, our CEO; ...
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...
Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...
Investing.com - Barclays reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ:BBIO). The firm estimates first-quarter U.S. Attruby revenue of $175 million versus ...
His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic ...
While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
JPMorgan said its survey of 28 physicians treating transthyretin amyloid cardiomyopathy, or ATTR-CM, pointed to steady uptake of BridgeBio’s drug Attruby among newly diagnosed patients and among those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results